The following are examples of hypotheses that can be considered in the development of the evaluation and design: The 1115 SUD waiver will increase access to SUD treatment options to Indiana Medicaid members. The 1115 SUD waiver will increase provider enrollment for SUD treatment for Indiana Medicaid members. The 1115 SUD waiver will reduce readmission rates to emergency departments and inpatient hospital settings for Indiana Medicaid members who have had a previous admission for substance abuse treatment. The 1115 SUD waiver will increase the percentage of Indiana Medicaid members affected by substance abuse who seek treatment for substance abuse. The 1115 SUD waiver will promote the entire continuum of SUD treatment options. 2.4.1.1.b. Measures The draft evaluation design must discuss the outcome measures that shall be used in evaluating the impact of the demonstration during the period of approval, including: A description of each outcome measure selected, including clearly defined numerators and denominators, and National Quality Forum (NQF) numbers (as applicable). Identifying the measure steward organization responsible for providing the required measure information for the measure, making any necessary updates to the measure, and informing stakeholders about any changes made to the measures. The baseline value for each measure and the method by which the baselines were established. The sampling methodology for assessing these outcomes including the margin of error, confidence level and response distribution, and sample size. 2.4.1.1.c. Sources of Measures Measure sets could include of Health Care Quality CMS’s Core Set Measures for Children in Medicaid and CHIP, Consumer Assessment of Health Care Providers and Systems (CAHPS), the Initial Core Set of Health Care Quality Measures for Medicaid-Eligible Adults and/or measures endorsed by the National Quality Forum (NQF). 2.4.1.1.d. Evaluation Requirements
The following are examples of hypotheses that can be considered in the development of the evaluation and design: The 1115 SUD waiver will increase access to SUD treatment options to Indiana Medicaid members. The 1115 SUD waiver will increase provider enrollment for SUD treatment for Indiana Medicaid members. The 1115 SUD waiver will reduce readmission rates to emergency departments and inpatient hospital settings for Indiana Medicaid members who have had a previous admission for substance abuse treatment. The 1115 SUD waiver will increase the percentage of Indiana Medicaid members affected by substance abuse who seek treatment for substance abuse. The 1115 SUD waiver will promote the entire continuum of SUD treatment options. 2.4.1.1.b. Measures The draft evaluation design must discuss the outcome measures that shall be used in evaluating the impact of the demonstration during the period of approval, including: A description of each outcome measure selected, including clearly defined numerators and denominators, and National Quality Forum (NQF) numbers (as applicable). Identifying the measure steward organization responsible for providing the required measure information for the measure, making any necessary updates to the measure, and informing stakeholders about any changes made to the measures. The baseline value for each measure and the method by which the baselines were established. The sampling methodology for assessing these outcomes including the margin of error, confidence level and response distribution, and sample size. 2.4.1.1.c. Sources of Measures Measure sets could include CMS’s Core Set of Health Care Quality Measures for Children in Medicaid and CHIP, Consumer Assessment of Health Care Providers and Systems (CAHPS), the Initial Core Set of Health Care Quality Measures for Medicaid-Eligible Adults and/or measures endorsed by the National Quality Forum (NQF). 2.4.1.1.d. Evaluation Requirements
061atth.docx